Trilaciclib and Lurbinectedin for Small Cell Lung Cancer
Study of Trilaciclib and Lurbinectidin
Recruiting
Phase 2
Interventional Study
Lung Cancer
Small-cell Lung Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 30 (estimated)
- Sponsor
- UNC Lineberger Comprehensive Cancer Center · Other
Who this trial is looking for
This trial is looking for adults with small cell lung cancer who have received prior treatments. Participants will take Trilaciclib along with Lurbinectedin to see how these medications work together and impact side effects.
Are You a Good Fit for This Trial?
You may be able to join if
- I am at least 18 years old.
- I have given my written consent to participate.
- I have a performance status of 0-1.
- I have measurable disease based on recent evaluations.
- I have received treatment with a platinum agent or PDL1 agent.
You may not be able to join if
- I have an active infection that needs treatment.
- I am pregnant or breastfeeding.
- I have taken any investigational drug in the last 4 weeks.
- I am allergic to either study medication.
- I am taking medications that are not allowed in the trial.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
Lung cancer is by far the leading cause of cancer death among both men and women worldwide and the second most common cancer in terms of new cases. Small cell lung cancer (SCLC) is the deadliest form of lung cancer. The standard first-line treatment is the combination of carboplatin, etoposide, and atezolizumab. While response rates for this regimen are high (roughly 60%), the duration of response…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
In order to participate in this study, a subject must meet all of the eligibility criteria outlined below.
Inclusion Criteria:
* Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.
* Age ≥ 18 years at the time of consent…
Contacts